For the week ending August 21, U.S. EIA crude oil inventories were 95,000 barrels, with an expected 597,000 barrels and a previous value of 4.405 million barrels. U.S. EIA Cushing, Oklahoma crude oil inventories for the same period were 1.176 million barrels, with a previous value of -1.314 million barrels.

As of the 23:00 close, most of the domestic futures main contracts rose. Rapeseed meal and liquefied petroleum gas (LPG) increased by nearly 2%; No.2 soybean, soybean meal, and asphalt rose by more than 1%; fuel oil and soybean oil were up nearly 1%. On the downside, soda ash and ethylene glycol (EG) dropped by over 2%; PET bottle-grade chips, short fiber, methanol, and paraxylene fell by more than 1%; caustic soda and coke declined by nearly 1%.

Spot gold falls below $4,590 per ounce, down 1.50% on the day.

China's INE crude oil futures main contract has just broken through the 570.0 yuan/barrel mark, now quoted at 570.4 yuan/barrel, up 1.05% for the day.

Revolution Medicines’ pancreatic cancer drug Daraxonrasib has been approved by U.S. regulators, making it the first drug targeting one of the key molecular pathogenic mechanisms of pancreatic cancer. The drug will be marketed under the name Rasonque and is considered one of the most important breakthroughs in pancreatic cancer treatment in recent years. According to data from the U.S. Food and Drug Administration (FDA), a late-stage clinical trial published in May showed that for a particularly